Search

Uri N Galili

from Shrewsbury, MA
Age ~77
Get Report
Also known as:
Uri U Galili, Uri G Galili, Uri Null
Phone and address:
275 Eaglehead Ter, Shrewsbury, MA 01545
(508) 757-2305
Related to:
Lynne M Greenberg, 65
Connected to:
Maelanie M Galima, 51Samuel V Galima, 36Nelson P Galimba, 69Enrico J Galimberti, 44Monica Galimberti, 69Phyllis Galimi, 86Scott Galimidi, 49Alex O Galimov, 58Elvira Galimova, 43Pawel Galimski, 36

Uri Galili Phones & Addresses

  • 275 Eaglehead Ter, Shrewsbury, MA 01545 (508) 757-2305
  • 27 Eaglehead Ter, Shrewsbury, MA 01545
  • 910 Michigan St, Chicago, IL 60605
  • New York, NY
  • Worcester, MA
  • San Francisco, CA
  • Chesterbrook, PA
  • 910 S Michigan Ave APT 1404, Chicago, IL 60605

Resumes

Resumes

Uri Galili Photo 1

Scientist

View page
Location:
Chicago, IL
Industry:
Research
Work:

Scientist
Uri Galili Photo 2

Uri Galili

View page

Publications

Us Patents

Methods And Compositions For Preventing Anti-Gal Production In Xenograft Recipients

View page
US Patent:
6613330, Sep 2, 2003
Filed:
Jul 27, 1999
Appl. No.:
09/362509
Inventors:
Uri Galili - Chicago IL
Assignee:
Rush University - Chicago IL
International Classification:
A61K 3944
US Classification:
4241831, 530350
Abstract:
Toxin complexes and methods for preventing immune rejection of xenografts are provided. Cell toxins are coupled to carriers that display ligands which allow the complex to be recognized by antigen binding sites (i. e. , specific B cell and T cell receptors) on the lymphocytes as the target cells responsible for the specific immune response. The toxin complexes interact with the specific receptors (antigen binding sites) on lymphocytes, and are internalized by these target cells. Once internalized, the toxin complex dissociates to release the cell toxin, which destroys the target cell. In one embodiment, the target cells are B lymphocytes and T lymphocytes, the antigen binding sites are anti-Gal B cell receptors and T cell receptors which interact with -gal epitopes displayed on an 1-acid glycoprotein carrier. In other embodiments, the toxin complex is directed by the corresponding ligands to target cells responsible for autoimmune diseases in which the specificity of the autoantibodies is defined.

Soft Tissue Xenografts

View page
US Patent:
6758865, Jul 6, 2004
Filed:
Feb 26, 2001
Appl. No.:
09/623729
Inventors:
Kevin R. Stone - Mill Valley CA
Uri Galili - Chicago IL
Assignee:
CrossCart, Inc. - San Francisco CA
International Classification:
A61F 236
US Classification:
623 2372, 623 1111, 623 1317, 623 1412, 623915
Abstract:
A method for preparing a soft tissue xenograft includes the steps of removing at least a portion of a soft tissue from a non-human animal to provide a xenograft; washing the xenograft in saline and alcohol; subjecting the xenograft to cellular disruption treatment; and either digesting the xenograft with a glycosidase or glycosidase digestion followed by treatment for sialylation. A soft tissue xenograft for implantation into a human includes a portion of a soft tissue from a non-human animal, wherein the portion has extracellular matrix and substantially only dead cells. The matrix and dead cells have substantially no surface -galactosyl moieties and have sialic acid molecules linked to at least a portion of surface carbohydrate moieties. Each of the xenografts of the invention has substantially the same mechanical properties as a corresponding native soft tissue.

Tumor Lesion Regression And Conversion In Situ Into Autologous Tumor Vaccines By Compositions That Result In Anti-Gal Antibody Binding

View page
US Patent:
7820628, Oct 26, 2010
Filed:
Feb 16, 2006
Appl. No.:
11/355804
Inventors:
Uri Galili - Shrewsbury MA, US
Assignee:
University of Massachusetts Medical School - Shrewsbury MA
International Classification:
A61K 31/70
A61K 31/715
C07H 1/00
C13K 5/00
C13K 7/00
US Classification:
514 25, 514 61, 5361231, 53612313
Abstract:
The present invention discloses that an intratumoral injection of: i) glycolipids with α-gal epitope; ii) gene vectors comprising an α1,3galactosyltransferase gene; or iii) a mixture of α1,3galactosyltransferase, neuraminidase, and uridine diphosphate galactose results in tumor regression and/or destruction. Binding of the natural anti-Gal antibody to de novo expressed tumoral α-gal epitopes induces inflammation resulting in an anti-Gal antibody mediated opsonization of tumor cells and their uptake by antigen presenting cells. These antigen presenting cells migrate to draining lymph nodes and activate tumor specific T cells thereby converting the treated tumor lesions into in situ autologous tumor vaccines. This therapy can be applied to patients with multiple lesions and in neo-adjuvant therapy to patients before tumor resection. In addition to the regression and/or destruction of the treated tumor, such a vaccine will help in the immune mediated destruction of micrometastases that are not detectable during the removal of the treated tumor.

Compositions And Methods For Wound Healing

View page
US Patent:
8084057, Dec 27, 2011
Filed:
Aug 17, 2009
Appl. No.:
12/542377
Inventors:
Uri Galili - Shrewsbury MA, US
Assignee:
University of Massachusetts - Boston MA
International Classification:
A61K 9/127
A61K 39/395
A61K 35/28
US Classification:
424450, 4241301, 424577
Abstract:
The present invention is related to the field of wound healing or tissue regeneration due to disease (i. e. , for example, cardiovascular diseases, osteoarthritic diseases, or diabetes). In particular, the present invention provides compositions and methods comprising molecules with linked α-gal epitopes for induction of recruitment of macrophages localized within or surrounding damaged tissue. The recruited macrophages and stem cells promote the repair and regeneration of the treated injured tissue. In some embodiments, the present invention provides treatments for tissue repair in normal subjects and in subjects having impaired healing capabilities, such as diabetic and aged subjects. In some embodiments, the present invention provides treatments for injured tissues such as brain, peripheral nerve, muscle, cartilage, bone, gastrointestinal tract and dysfunctional endocrine tissues.

Compositions And Methods For Wound Healing

View page
US Patent:
8440198, May 14, 2013
Filed:
Jul 17, 2008
Appl. No.:
12/669079
Inventors:
Uri Galili - Shrewsbury MA, US
Assignee:
University of Massachusetts - Boston MA
International Classification:
A61K 39/12
A61K 39/00
A61K 39/395
C07K 16/00
US Classification:
4241841, 4241551, 4241561, 4242181, 4242771, 424816, 5303871
Abstract:
The present invention is related to the field of wound healing or tissue regeneration due to disease (i. e. , for example, cardiovascular diseases, osetoarthritic diseases, or diabetes). In particular, the present invention provides compositions and methods comprising molecules with linked α-gal epitopes for induction of an inflammatory response localized within or surrounding damaged tissue. In some embodiments, the present invention provides treatments for tissue repair in normal subjects and in subjects having impaired healing capabilities, such as diabetic and aged subjects.

Bone Xenografts

View page
US Patent:
20040098135, May 20, 2004
Filed:
Nov 13, 2003
Appl. No.:
10/712165
Inventors:
Kevin Stone - Mill Valley CA, US
Uri Galili - Chicago IL, US
International Classification:
A61F002/28
US Classification:
623/023630, 008/094110, 623/919000
Abstract:
The invention provides an article of manufacture comprising a substantially non-immunogenic bone xenograft (X) for implantation into a defect (D) located in a bone portion () of a human. The invention further provides methods for preparing a bone xenograft (X) by removing at least a portion of bone from a non-human animal to provide a xenograft (X); washing the xenograft (X) in saline and alcohol; and subjecting the xenograft (X) to at least one of the treatments including exposure to ultraviolet radiation, immersion in alcohol, ozonic, and freeze/thaw cycling. In addition to or in lieu of the above treatments, the methods include a cellular disruption treatment, and digestion of the carbohydrate moieties of the xenograft (X) with a glycosidase followed by treatment for sialylation.

Immune Tolerance To Predetermined Antigens

View page
US Patent:
20040234511, Nov 25, 2004
Filed:
Feb 27, 2004
Appl. No.:
10/789955
Inventors:
Uri Galili - Chicago IL, US
Haruko Ogawa - Chicago IL, US
Assignee:
Rush University Medical Center
International Classification:
A61K048/00
US Classification:
424/093210
Abstract:
The present invention provides compositions and methods for inducing immune tolerance to one or more specific antigens in a host mammal. Generally, the methods involves engineering white blood cells, in vitro, to express an antigen which is not native to the host mammal. Cells engineered ex vivo are then introduced into the host mammal to induce immune tolerance to the expressed antigen.

Early Detection Of Recipient's Immune Response Against Heart Transplant

View page
US Patent:
20040241764, Dec 2, 2004
Filed:
May 23, 2004
Appl. No.:
10/852325
Inventors:
Uri Galili - Chicago IL, US
International Classification:
G01N033/53
G01N033/567
G01N033/537
G01N033/543
US Classification:
435/007200, 435/007920
Abstract:
A novel noninvasive immunological method for early detection of immune reactivity, primarily antibody reactivity, in heart transplant recipients prior to tissue damage or rejection is disclosed. The method utilizes donor tissue obtained before transplant and processed to obtain an antigen preparation comprising homogenized, fragmented donor cardiac tissue, including the posterior wall of the right atrium and the joining portion of the vena cava. This donor tissue is normally discarded before transplant. The methods include ELISA or light emitting immunoassays for measuring antibody binding. These methods are also applicable to allografts of other organs such as kidney. Such early detection of these immune responses enables a treating physician to modify the immunosuppressive treatment in order to prevent episodes of immune rejection and thus, to prevent damage of the transplanted organ.
Control profile
Uri N Galili from Shrewsbury, MA, age ~77 Get Report